Status:
RECRUITING
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
Lead Sponsor:
Tianjin Medical University Second Hospital
Conditions:
Malignant Pleural Mesothelioma, Advanced
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously...
Detailed Description
By monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (PD-1) inhibitors, we anal...
Eligibility Criteria
Inclusion
- Age 18-75 years old (including boundary values), regardless of gender.
- Confirmed as late stage MPM patients who have failed immunotherapy.
- The patient or their legal representative can understand and sign the informed consent form.
- At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods.
- ECOG score 0-2.
Exclusion
- Physicians participating in the study believe that patients may not be able to provide continuous follow-up information.
- Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases).
- Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)
Key Trial Info
Start Date :
July 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06031636
Start Date
July 20 2023
End Date
July 31 2026
Last Update
September 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical Unversity Second Hospital
Tianjin, Tianjin Municipality, China